Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens

Author(s): Hideyuki Ikeda

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 14 , 2003

Become EABM
Become Reviewer


Identification of CD8+ and CD4+ T-cell defined tumor antigens has opened the way for possible cancer immunotherapy. Peptide-based active immunization has begun mainly targeting melanoma. Surprisingly, some objective responses were obtained in the initial trials, leading to the accumulation of an explosive number of such antigens. Serological screening of cDNA expression libraries accelerated the identification of immunodominant antigens, resulting in the emergence of the concept of a “cancer-testis antigen.” On the other hand, an advance in basic immunology has been promptly adopted: dendritic cells, as potent professional antigen presenting cells have been preferentially used in combination with the antigen in clinical trials both in vivo and in vitro. Tetramer analysis provided a powerful tool to directly monitor antigen-specific T cells in vivo in these trials. Moreover, adoptive transfer of antigen-specific T cells has added a new perspective to recent cancer immunotherapy.

Keywords: t-cell defined tumor antigen, epitope or agretope-altered peptide, cytotoxic t lymphocytes (ctl), cancer-testis (ct) antigen, cytokine, cancer immunotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [1133 - 1138]
Pages: 6
DOI: 10.2174/1381612033454973
Price: $65

Article Metrics

PDF: 2